What are the recommended antibiotics for treating Klebsiella and Enterobacter infections in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antibiotics for Klebsiella and Enterobacter Infections

For community-acquired Klebsiella and Enterobacter infections of mild-to-moderate severity, use ertapenem, ceftriaxone plus metronidazole (if anaerobic coverage needed), or piperacillin-tazobactam; for severe community-acquired or healthcare-associated infections, use carbapenems (meropenem, imipenem-cilastatin, or doripenem) as first-line therapy. 1

Community-Acquired Infections

Mild-to-Moderate Severity

For community-acquired intra-abdominal or urinary infections caused by Klebsiella or Enterobacter species:

Preferred regimens 1:

  • Ertapenem 1 g IV every 24 hours
  • Ceftriaxone 1-2 g IV every 12-24 hours (± metronidazole 500 mg every 8-12 hours if anaerobic coverage needed)
  • Piperacillin-tazobactam 3.375 g IV every 6 hours
  • Moxifloxacin 400 mg IV every 24 hours (only if local E. coli susceptibility ≥90%) 1

Avoid ampicillin-sulbactam due to high resistance rates among community-acquired E. coli, which often predicts cross-resistance patterns in Enterobacteriaceae 1.

High-Severity Community-Acquired Infections

For patients with APACHE II scores ≥15, immunosuppression, or significant comorbidities 1:

Preferred carbapenems 1:

  • Meropenem 1 g IV every 8 hours
  • Imipenem-cilastatin 500 mg IV every 6 hours or 1 g every 8 hours
  • Doripenem 500 mg IV every 8 hours

Alternative regimens 1:

  • Piperacillin-tazobactam 3.375 g IV every 6 hours (or 4.5 g every 6 hours for severe infections)
  • Cefepime 2 g IV every 8-12 hours plus metronidazole 500 mg every 6 hours
  • Levofloxacin 750 mg IV every 24 hours plus metronidazole (only if quinolone resistance <10% locally) 1

Healthcare-Associated and Multidrug-Resistant Infections

ESBL-Producing Klebsiella/Enterobacter

Carbapenems remain the gold standard for ESBL-producing Enterobacteriaceae 2, 3:

  • Meropenem 1 g IV every 8 hours (preferred)
  • Imipenem-cilastatin/relebactam 1.25 g IV every 6 hours 2
  • Ertapenem 1 g IV every 24 hours (for non-critically ill patients)

Carbapenem-sparing alternatives (if organism susceptible) 4, 5:

  • Fluoroquinolones (ciprofloxacin 400 mg IV every 12 hours or levofloxacin 750 mg IV every 24 hours) can be considered if in vitro susceptibility confirmed, though carbapenems show superior outcomes 4
  • Piperacillin-tazobactam may be used for susceptible ESBL strains, though clinical data are mixed 5

Carbapenem-Resistant Enterobacteriaceae (CRE)

For KPC-producing Klebsiella 2, 6, 7:

  • Meropenem-vaborbactam 4 g IV every 8 hours (first-line choice) 7
  • Imipenem-cilastatin/relebactam 1.25 g IV every 6 hours (alternative for KPC) 2, 6
  • Ceftazidime-avibactam 2.5 g IV every 8 hours (if KPC-producing and ceftazidime-avibactam susceptible) 2

For OXA-48-like producing organisms 6, 8:

  • Ceftazidime-avibactam 2.5 g IV every 8 hours (preferred) 6, 8
  • Consider adding to standard therapy rather than monotherapy for improved outcomes 8

For metallo-β-lactamase (MBL) producers 6, 3:

  • Ceftazidime-avibactam 2.5 g IV every 8 hours plus aztreonam 1-2 g IV every 6-8 hours 2, 6
  • Cefiderocol (alternative for MBL-producing organisms) 6

Salvage options for extensively resistant CRE 2:

  • Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours plus tigecycline 100 mg IV loading, then 50 mg IV every 12 hours
  • Polymyxin-based combinations with meropenem (extended infusion) or tigecycline 2

Critical Considerations

Susceptibility testing is mandatory for Klebsiella, Enterobacter, and other Enterobacteriaceae, as these organisms frequently harbor resistance mechanisms 1. Extended-infusion meropenem (over 3 hours) should be considered when MIC ≥8 mg/L 2.

Enterococcal coverage is NOT routinely needed for community-acquired infections 1, but should be added for healthcare-associated infections, particularly in postoperative patients, those with prior cephalosporin exposure, immunocompromised patients, or those with valvular heart disease 1.

Aminoglycosides are not recommended for routine empiric therapy in adults due to toxicity, though they may be added for severe infections with documented resistant organisms 1.

Duration of therapy: 5-7 days for uncomplicated urinary tract infections and intra-abdominal infections with adequate source control; 10-14 days for bloodstream infections; individualize based on clinical response 2.

References

Research

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023

Research

Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2008

Related Questions

What antibiotic regimen should be started for a patient whose sputum culture grows >100,000 CFU/mL ESBL‑producing Escherichia coli, 50–60,000 CFU/mL ESBL‑producing Proteus mirabilis, and 50–60,000 CFU/mL Staphylococcus aureus?
What is the recommended treatment for an adult infection caused by ESBL-producing Escherichia coli?
What is the appropriate antibiotic management for necrotizing pancreatitis, including indications for initiation, recommended broad‑spectrum regimens, dosing, duration, and adjustments for β‑lactam allergy or multidrug‑resistant organisms?
What is the best treatment option for a multidrug-resistant Klebsiella pneumoniae infection that is susceptible to gentamicin?
Which antibiotics are appropriate for treating Klebsiella infections in adults, including options for extended‑spectrum β‑lactamase‑producing strains?
What are the possible causes of an isolated mild aspartate aminotransferase (AST) elevation in a nondrinking patient with normal body mass index, normal alanine aminotransferase (ALT) and alkaline phosphatase (ALP), normal liver imaging and biopsy, and prior cardiology and gastroenterology evaluation, and is further workup necessary?
What is the pathophysiology of cytomegalovirus (CMV) infection?
What is the appropriate vancomycin dosing regimen for an adult with impaired renal function, including adjustments for intermittent hemodialysis and continuous renal replacement therapy?
What is the recommended dosing and administration of mucomyst (acetylcysteine) nebulized at 200 mg every 6 hours?
What is the appropriate evaluation for bilateral femoral head avascular necrosis?
In a stable 75-year-old woman with two episodes of hematochezia, dizziness, and hemoglobin 9.2 g/dL, what is the next appropriate management step?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.